Acrivon Therapeutics, Inc. Common StockACRVNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 90% recommend buying.

Consensus Rating

Buy

10 analysts·Moderate coverage

90%

Rating Distribution

Strong Buy

00%

Buy

990%

Hold

110%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 1120% higher.

Bear Case

$17.00

+850%

Consensus

$21.83

+1120%

Bull Case

$30.00

+1576%

Price Range10 analysts

Low

Consensus

High

$17.00

$30.00

Current Target

Current Price

$1.79

Upside to Target

$20.04

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-1.96(7 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+645.91%

EPS—

FY2028

Rev+346.94%

EPS—

FY2029

Rev+132.88%

EPS—

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+7.9%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 14, 2024BMO Capital

Acrivon Therapeutics Inc (ACRV) PT Lowered to $27 at BMO Capital

Target:$27.00

+240.9%from $7.92

Sep 16, 2024BMO Capital

Acrivon Therapeutics price target raised to $28 from $25 at BMO Capital

Target:$28.00

+214.3%from $8.91

Aug 13, 2024Oppenheimer

Acrivon Therapeutics price target lowered to $18 from $21 at Oppenheimer

Target:$18.00

+147.9%from $7.26

May 14, 2024Oppenheimer

Oppenheimer Reiterates Outperform Rating on Acrivon Therapeutics Inc (ACRV)

Target:$21.00

+151.2%from $8.36

May 14, 2024H.C. Wainwright

Acrivon Therapeutics price target raised to $22 from $20 at H.C. Wainwright

Target:$22.00

+163.6%from $8.35

May 14, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on Acrivon Therapeutics Inc (ACRV)

Target:$25.00

+193.8%from $8.51

Apr 25, 2024Piper Sandler

Acrivon Therapeutics Inc (ACRV) PT Raised to $30 at Piper Sandler

Target:$30.00

+226.1%from $9.20

Apr 25, 2024JMP Securities

Acrivon Therapeutics price target raised to $17 from $14 at JMP Securities

Target:$17.00

+78.9%from $9.50

Mar 28, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Acrivon Therapeutics Inc (ACRV), views ACR-368 'benefit/risk as favorable'

Target:$20.00

+178.4%from $7.18

Dec 12, 2022Jefferies

Jefferies Initiates Coverage On Acrivon Therapeutics with Buy Rating, Announces Price Target of $17

Target:$17.00

+36.0%from $12.50

Dec 11, 2022Piper Sandler

Acrivon Therapeutics initiated with an Overweight at Piper Sandler

Target:$25.00

+100.0%from $12.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance